Framework focuses on improving patient identification

Two health information exchange organizations have issued a white paper with a framework to improve patient matching without the use of a national patient identifier system.

That's because Congress passed appropriations legislation for fiscal year 1999 that prohibited the Department of Health and Human Services (HHS) from using federal funds to implement a national identifier system, citing privacy concerns. Language regarding the prohibition has been included in appropriation bills each year since. Several stakeholder organizations, such as CHIME, have urged lawmakers to lift the congressional ban on the use of federal funds to develop such a system.

The white paper was authored by the Care Connectivity Consortium and the Sequoia Project. The white paper includes the funding of a case study conducted by Intermountain Healthcare that increased successful match rates among exchange partners from 10 percent to greater than 95 percent, according to a release. Project participants identified a set of key patient data attributes and drove that increase by standardizing the way such attributes were recorded. The organizations developed their recommendations partly on that project, as well as other local HIE participants. 

In addition to standardizing data formats, the white paper includes a "number of specific rules" for patient matching such as having technical staff not rely on any one specific identifier and using exact character-by-character matching.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.